EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease

Davina Biel iD, Anna Steward, Anna Dewenter, Amir Dehsarvi, Zeyu Zhu, Sebastian N Roemer-Cassiano, Lukas Frontzkowski, Fabian Hirsch, Carla Palleis, Günter Höglinger, Matthias Brendel, Nicolai Franzmeier iD und 1 weitere

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70783 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Davina Biel und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, tau Proteins, Cognitive Dysfunction. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Alzheimer's Association, Munich Cluster for Systems Neurology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION With anti‐amyloid beta (Aβ) therapies approved for Alzheimer's disease (AD), surrogate biomarkers are needed to monitor clinical treatment efficacy. Therefore, we systematically compared longitudinal changes in A/T/N biomarkers (amyloid‐positron emission tomography [PET], tau‐PET, plasma phosphorylated tau at threonine 217 [p‐tau 217 ], and magnetic resonance imaging) for tracking cognitive changes. METHODS We analyzed longitudinal biomarker and cognitive change rates from the Alzheimer's Disease Neuroimaging Initiative ( N = 141) and Anti‐Amyloid Treatment in Asymptomatic Alzheimer's (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) ( N = 151), estimated using linear mixed models. Using linear models, we tested biomarker changes as predictors of cognitive changes, comparing predictive strengths across biomarkers using bootstrapping. RESULTS Tau‐PET, plasma p‐tau217, and cortical thickness changes accurately tracked change rates in Mini‐Mental State Examination, Alzheimer's Disease Assessment Scale‐Cognitive Subscale 13‐item version, Clinical Dementia Rating‐Sum of Boxes, and Preclinial Alzheimer Cognitive Composite scores. In contrast, amyloid‐PET change rates were not linked to cognitive changes. DISCUSSION Plasma p‐tau 217 offers a cost‐effective AD‐specific alternative to tau‐PET and could potentially be implemented for monitoring cognitive changes in AD trials, while amyloid‐PET lacks utility. Cortical thickness changes accurately track cognitive changes but may be confounded by pseudo‐atrophy in anti‐Aβ treatments. Highlights Longitudinal changes in tau‐PET, plasma p‐tau 217 , cortical thickness – but not amyloid‐PET – effectively track cognitive decline. Cortical thickness may be confounded by pseudo‐atrophy in anti‐Aβ trials. Plasma p‐tau 217 is a robust and cost‐effective alternative to tau‐PET as an AD‐specific surrogate biomarker for monitoring cognitive changes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkerstau ProteinsCognitive DysfunctionHumansPositron-Emission TomographyMaleFemaleLongitudinal StudiesAgedMagnetic Resonance ImagingAmyloid beta-PeptidesAged, 80 and overBrainCognition

Stichwörter der Autor:innen

Alzheimer's diseaseamyloid‐PETcortical thicknessplasma phosphorylated taup‐tautau‐PETtreatment monitoring

Substanzen

Biomarkerstau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
  • Department of Neurology, University Hospital, LMU Munich, Munich, Germany.
  • Department of Nuclear Medicine, University Hospital, LMU Munich, Munich, Germany.
  • German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • The Sahlgrenska Academy, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, Mölndal and Gothenburg, University of Gothenburg, Mölndal and Gothenburg, Sweden.

ORCID-Profile: Davina Biel, Nicolai Franzmeier

Förderung

  • NIA NIH HHS
  • Alzheimer's Association
  • Munich Cluster for Systems Neurology

Zitieren

APA

Biel, D., Steward, A., Dewenter, A., Dehsarvi, A., Zhu, Z., Roemer-Cassiano, S. N., Frontzkowski, L., Hirsch, F., Palleis, C., Höglinger, G., Brendel, M., Franzmeier, N., & Alzheimer's Disease Neuroimaging Initiative (ADNI) (2025). A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70783

Vancouver

Biel D, Steward A, Dewenter A, Dehsarvi A, Zhu Z, Roemer-Cassiano SN, et al. A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70783

BibTeX
@article{Biel2025,
  author = {Biel, Davina and Steward, Anna and Dewenter, Anna and Dehsarvi, Amir and Zhu, Zeyu and Roemer-Cassiano, Sebastian N and Frontzkowski, Lukas and Hirsch, Fabian and Palleis, Carla and Höglinger, Günter and Brendel, Matthias and Franzmeier, Nicolai and Alzheimer's Disease Neuroimaging Initiative (ADNI), Alzheimer's Disease Neuroimaging Initiative (ADNI)},
  title = {A systematic comparison of ATN biomarkers for monitoring longitudinal cognitive changes in Alzheimer's disease},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70783}
}
Kostenlos starten →